潜在治疗 2019 年冠状病毒病药物的心血管安全性。
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
机构信息
Jersey City Medical Center, Jersey City, New Jersey.
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
出版信息
Am J Cardiol. 2020 Aug 1;128:147-150. doi: 10.1016/j.amjcard.2020.04.054. Epub 2020 May 16.
Abstract
Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure, and mortality have been reported with the use of these drugs. It is important to have knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.
摘要
2019 年冠状病毒病（COVID-19）已成为全球性大流行疾病。在大多数国家仍未得到控制，目前尚无特效疗法。目前正在研究各种药物来治疗该病。已知患有心血管疾病等基础疾病的患者预后更差。氯喹/羟氯喹、阿奇霉素、瑞德西韦和洛匹那韦/利托那韦目前正在临床试验中，显示出一定的前景。这些药物的使用与传导障碍、心力衰竭和死亡率有关。在将这些药物用于 COVID-19 患者之前，了解这些药物的潜在心脏毒性作用非常重要，这有助于更好地分配医疗资源和改善临床结果。
相似文献
1
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.潜在治疗 2019 年冠状病毒病药物的心血管安全性。
Am J Cardiol. 2020 Aug 1;128:147-150. doi: 10.1016/j.amjcard.2020.04.054. Epub 2020 May 16.
2
Psychopharmacology of COVID-19.新型冠状病毒肺炎的精神药理学。
Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18.
3
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.瑞德西韦、洛匹那韦/利托那韦和氯喹/羟氯喹影响新型 SARS-CoV-2 的抗病毒机制研究进展。
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
4
Some drugs for COVID-19.一些用于治疗新冠肺炎的药物。
Med Lett Drugs Ther. 2020 Apr 6;62(1595):49-50.
5
Race to find COVID-19 treatments accelerates.寻找新冠病毒治疗方法的竞赛加速。
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
6
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.新型冠状病毒病治疗药物的研究进展。
Pharmacotherapy. 2020 May;40(5):416-437. doi: 10.1002/phar.2398. Epub 2020 May 6.
7
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.新型冠状病毒肺炎治疗中药物组合的安全性评估：基于计算毒理学和基因组学的大数据挖掘方法。
Toxicol Appl Pharmacol. 2020 Nov 1;406:115237. doi: 10.1016/j.taap.2020.115237. Epub 2020 Sep 11.
8
Early experience with remdesivir in SARS-CoV-2 pneumonia.瑞德西韦治疗 SARS-CoV-2 肺炎的早期经验。
Infection. 2020 Oct;48(5):779-782. doi: 10.1007/s15010-020-01448-x. Epub 2020 May 16.
9
Treatment options for COVID-19: The reality and challenges.治疗 COVID-19 的选择：现实与挑战。
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4.
10
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2：洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
引用本文的文献
1
Investigating the effects of remdesivir on corrected QT interval in patients with severe COVID-19 disease: a historical cohort study.研究瑞德西韦对重症新型冠状病毒肺炎患者校正QT间期的影响：一项历史性队列研究。
BMC Cardiovasc Disord. 2024 Dec 4;24(1):700. doi: 10.1186/s12872-024-04380-2.
2
Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study.海洋药物作为潜在的 SARS-CoV-2 非结构蛋白抑制剂：一项计算机研究。
J Mol Model. 2023 May 12;29(6):176. doi: 10.1007/s00894-023-05574-9.
3
Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia.哥伦比亚新冠疫情期间医院层面与QT间期延长相关药物的使用情况
Int J Vasc Med. 2022 Sep 21;2022:3045942. doi: 10.1155/2022/3045942. eCollection 2022.
4
A case report on the association between QTc prolongation and remdesivir therapy in a critically ill patient.一名重症患者中QTc延长与瑞德西韦治疗之间关联的病例报告。
IDCases. 2022;29:e01572. doi: 10.1016/j.idcr.2022.e01572. Epub 2022 Jul 15.
5
Transcriptional Effects of Candidate COVID-19 Treatments on Cardiac Myocytes.新型冠状病毒肺炎候选治疗药物对心肌细胞的转录影响
Front Cardiovasc Med. 2022 May 24;9:844441. doi: 10.3389/fcvm.2022.844441. eCollection 2022.
6
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.氯喹和阿奇霉素在健康志愿者中的药代动力学和心电图评估。
Clin Pharmacol Ther. 2022 Oct;112(4):824-835. doi: 10.1002/cpt.2665. Epub 2022 Jun 22.
7
The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.瑞德西韦在体外影响心脏和肾脏细胞功能、代谢和增殖的潜力。
Arch Toxicol. 2022 Aug;96(8):2341-2360. doi: 10.1007/s00204-022-03306-1. Epub 2022 May 17.
8
Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid-19 pneumonia.线性混合模型分析评估瑞德西韦不良反应与轻度 COVID-19 肺炎患者年龄和性别之间的相关性。
J Med Virol. 2022 Aug;94(8):3783-3790. doi: 10.1002/jmv.27800. Epub 2022 May 12.
9
A Comparative NLP-Based Study on the Current Trends and Future Directions in COVID-19 Research.一项基于自然语言处理的关于COVID-19研究当前趋势和未来方向的比较研究。
IEEE Access. 2021 May 20;9:78341-78355. doi: 10.1109/ACCESS.2021.3082108. eCollection 2021.
10
Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review.瑞德西韦对心血管系统的潜在心脏毒性作用：文献综述。
Cardiovasc Toxicol. 2022 Mar;22(3):268-272. doi: 10.1007/s12012-021-09703-9. Epub 2021 Oct 13.
本文引用的文献
1
Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis.心血管疾病与 2019 年冠状病毒病（COVID-19）严重程度的关联：一项荟萃分析。
Curr Probl Cardiol. 2020 Aug;45(8):100617. doi: 10.1016/j.cpcardiol.2020.100617. Epub 2020 Apr 28.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
3
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
4
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病（COVID-19）疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
5
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
6
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
7
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.氯喹和羟氯喹相关的心脏并发症：文献系统综述。
Drug Saf. 2018 Oct;41(10):919-931. doi: 10.1007/s40264-018-0689-4.
8
QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.埃博拉病毒感染患者接受法匹拉韦治疗期间的QTc间期延长
PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034. doi: 10.1371/journal.pntd.0006034. eCollection 2017 Dec.
9
Use of azithromycin and risk of ventricular arrhythmia.阿奇霉素的使用与室性心律失常风险
CMAJ. 2017 Apr 18;189(15):E560-E568. doi: 10.1503/cmaj.160355.
10
Azithromycin Causes a Novel Proarrhythmic Syndrome.阿奇霉素会引发一种新型的心律失常综合征。
Circ Arrhythm Electrophysiol. 2017 Apr;10(4). doi: 10.1161/CIRCEP.115.003560.
Zotero 插件